Loading patent…
AssigneesGenentech, Inc., Biogen Idec MA Inc.
InventorsYen-Ming Hsu, Leonid Gorelik, Tatiana Novobrantseva, Joanne Quan, Flavius Martin, Susan L. Kalled
Estimating the term…
BAFF plays a central role in acquired immunity. The disclosure identifies BAFF responsive genes that are substantially upregulated by administration of BAFF and substantially downregulated by treatment with a BAFF antagonist. Specific genes are NF-κB2, CD23, H2-Mβ (the beta chain of H2-DM), Fig-1, and OBF-1. The disclosure provides methods and compositions for monitoring the activity of a BAFF antagonist in a mammal; monitoring BAFF activity in a mammal; identifying a mammal to be treated with a BAFF antagonist; and related uses. Such methods include detecting one or more molecules selected from the group consisting of Fig-1 molecule, OBF-1 molecule, and H2-Mβ molecule in a biological sample of the mammal, and optionally further detecting NF-κB2 molecule and/or CD23 molecule in the biological sample.
1-2. (canceled)
A method for monitoring efficacy of a BAFF antagonist in a mammal comprising the steps of administering the BAFF antagonist to the mammal and detecting at the transcriptional and/or translational level one or both molecules selected from the group consisting of NF-κB2 molecule and CD23 molecule in a biological sample of the treated mammal, wherein the level of expression, relative to a control, of at least one of the detected molecules indicates efficacy of the BAFF antagonist in the mammal.
A method for monitoring BAFF activity in a mammal, comprising the step of detecting at the transcriptional and/or translational level(s) in a biological sample of the mammal one or more molecules selected from the group consisting of H2-Mβ molecule, Fig-1 molecule, OBF-1 molecule, wherein elevated expression, relative to a control, of at least one of the detected molecules indicates elevated BAFF activity.
A method for monitoring BAFF activity in a mammal, comprising the step of detecting at the transcriptional level in a biological sample of the mammal one or both molecules selected from the group consisting of NF-κB2 molecule and CD23 molecule, wherein elevated expression, relative to a control, of at least one of the detected molecules indicates elevated BAFF activity in the mammal.
A method of identifying a mammal treated or to be treated with a BAFF antagonist, comprising the step of providing a sample from a mammal and detecting one at the transcriptional and/or translational level(s) or more molecules selected from the group consisting of Fig-1 molecule, OBF-1 molecule, and H2-Mβ molecule in the sample of the mammal, wherein elevated expression, relative to a control, of at least one of the detected molecules indicates that the mammal should be treated with the BAFF antagonist.
A method of identifying a mammal treated or to be treated with a BAFF antagonist, comprising the steps of providing a biological sample from a mammal and detecting at the transcriptional level in a biological sample of the mammal one or both molecules selected from the group consisting of NF-κB2 molecule and CD23 molecule, wherein elevated expression, relative to a control, of at least one of the detected molecules indicates that the mammal should be treated with the BAFF antagonist.
21-25. (canceled)
28-56. (canceled)
Dependencies are inferred from the claim text.